On March 30, 2021, Illumina made available a standard contract to any U.S. oncology customer.
At a high level, the terms of the standard contract include the following:
- A 12-year supply contract for Illumina’s sequencing products sold in the United States, specifically, Illumina’s NextSeq and NovaSeq instruments and sequencing consumables.
- Guaranteed access to the latest sequencing products, and related product and support services.
- No price increases for the sequencing products covered by the agreement.
- Guaranteed lower pricing for the sequencing products by 2025: the cost per gigabase of sequencing on Illumina’s highest throughput instrument, using the highest throughput flow cell, will be at least 43% lower than the comparable cost per gigabase today, under Illumina’s standard terms.
- Illumina will not discontinue any of the sequencing products supplied under the agreement as long as an oncology customer continues to purchase that product.
- Provision of any documentation or information reasonably required to seek FDA approval or FDA marketing authorization to sell a clinical test using the sequencing products supplied under the agreement.
- Any oncology customer can also enter into a separate agreement to develop a distributable in vitro diagnostic kitted test using Illumina’s FDA-approved instruments.
Additional terms and conditions apply. The standard supply contract (and standard IVD agreement terms) may be viewed here. On September 8, 2021, Illumina made available an addendum to the supply contract which may be viewed here.
Since its initial publication, Illumina has updated the contents in Appendix 1 to the Supply Agreement in accordance with the terms therein. Those updates are listed below, with the most recent updates appearing first.
On May 16, 2023, Illumina added the following additional Products in a newly revised Appendix 1 and updated the table of Supplied Products. This revised version continues to reflect Illumina’s 2023 pricing year standard list price.
- Certified Pre-Owned NovaSeq 6000 Sequencing Systems are now available and are eligible for Open Offer pricing.
- View the additional Products and updated schedules in the revised Appendix 1 here.
On February 23, 2023, Illumina added the following additional Products in a newly revised Appendix 1 and updated the table of Supplied Products to reflect Illumina’s 2023 pricing year standard list price.
- A new sequencing consumable for the NovaSeq X is now available and eligible for Open Offer pricing
View the additional Products and updated schedules in the revised Appendix 1 here.
On December 16, 2022, Illumina added the following additional Products in a newly revised Appendix 1:
- A new instrument is now available and eligible for Open Offer pricing
View the additional Products and updated schedules in the revised Appendix 1 here. These terms are available to any U.S. oncology customer as part of the standard contract.
On November 15, 2022, Illumina added the following additional Products in a newly revised Appendix 1:
- Three new consumables associated with the NextSeq 1000/2000 are now available and eligible for Open Offer pricing
View the additional Products and updated schedules in the revised Appendix 1 here. These terms are available to any U.S. oncology customer as part of the standard contract.
On September 29, 2022, Illumina added the following additional Products in a newly revised Appendix 1:
- New instruments, consumables, and service contracts associated with the NovaSeq™ X Plus and NovaSeq™ 6000Dx are now available and eligible for Open Offer pricing (with select items available October 3, 2022)
View the additional Products and updated schedules in the revised Appendix 1 here. These terms are available to any U.S. oncology customer as part of the standard contract.
On August 19, 2022, Illumina made the following additional discounts available in a newly revised Appendix 1 to further reduce prices for customers:
- Discounts tiers on Service Contracts are now calculated using a customer’s Instrument Credits instead of their installed instrument count (Tables 3 and 4)
- A new higher credit, higher discount tier to the Universal Service Contract Discount Schedule (Table 4)
- All tables were revised in our customer’s favor to eliminate tier overlap (Tables 1, 2, and 4)
- A new product is now eligible for Open Offer pricing
View the additional new discount tiers and schedules in the revised Appendix 1 here. These terms are available to any U.S. oncology customer as part of the standard contract.
On January 6, 2022, Illumina made additional discounts available in a revised Appendix 1. Illumina is continuing to reduce prices for customers under the Open Offer after the August 18, 2021 acquisition of GRAIL. The following new discount tiers and schedules will be available to Open Offer customers as of January 6, 2022:
- A new, higher volume, higher discount tier to the Universal Consumables Discount Schedule (Table 1)
- Two new higher credit, higher discount tiers to the Universal Hardware Discount Schedule (Table 2)
- A new discount schedule for instrument warranty service contracts entitled, “Universal Service Contract Discount Schedule” (Table 4)
- A new consumable is now eligible for Open Offer pricing.
View the additional new discount tiers and schedules in the revised Appendix 1 here (changes highlighted). These terms are available to any U.S. oncology customer as part of the standard contract.
U.S. oncology customers can enter into any of the following contracts to develop distributable in vitro diagnostic kitted tests on an Illumina platform, which contracts apply the same terms as in the IVD term sheet:
- An agreement to develop and commercialize an unlimited number of in vitro diagnostic test kits for use on Illumina’s NextSeq 550Dx and future Illumina regulatory-approved Dx sequencing platforms, for a term of 15 years. View contract here.
- An agreement to develop and commercialize up to three in vitro diagnostic test kits for use on Illumina’s NextSeq 550Dx, for a term of 10 years. View contract here.
- An agreement to develop and commercialize up to three in vitro diagnostic test kits for use on the expected Illumina NovaSeq-based regulatory-approved Dx sequencing platform, for a term of 10 years. Illumina does not guarantee that such a platform will receive regulatory approval in any jurisdiction. View contract here.
GRAIL’s Product and Service Purchasing may be viewed here.